🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. Dimethyl fumarate

    Biogen

    Multiple Sclerosis

    approved small molecule completed

    1 trial

  2. Doxorubicin Accord 2 mg/ml koncentrat till infusionsvätska, lösning, Paclitaxel Accord 6 mg/ml koncentrat till infusionsvätska, lösning, Docetaxel Ebewe 10 mg/ml koncentrat till infusionsvätska, lösning, Epirubicin Accord 2 mg/ml injektions-/infusionsvätska, lösning, Sendoxan pulver till injektionsvätska, lösning

    The George Institute

    Breast cancer female NOS

    approved small molecule active

    1 trial

  3. Dupilumab

    Regeneron UK Limited

    Eosinophilic Oesophagitis

    approved small molecule active

    1 trial

  4. Dupilumab

    Regeneron UK Limited

    Keloid

    approved small molecule completed

    2 trials

  5. Dupilumab

    Regeneron UK Limited

    Moderate-to-Severe Atopic Dermatitis

    approved small molecule completed

    2 trials

  6. Dupilumab

    Regeneron UK Limited

    Eosinophilic Esophagitis

    approved small molecule active

    4 trials

  7. Dupilumab

    Regeneron UK Limited

    Eczema

    approved small molecule active

    1 trial

  8. Dupilumab

    Regeneron UK Limited

    Dermatitis, Atopic

    approved small molecule active

    5 trials

  9. Dupilumab

    Regeneron UK Limited

    Dermal Hypersensitivity Reaction

    approved small molecule completed

    1 trial

  10. Dupilumab

    Regeneron UK Limited

    Chronic Rhinosinusitis With Nasal Polyps

    approved small molecule completed

    1 trial

  11. Dupilumab

    Regeneron UK Limited

    Chronic Obstructive Pulmonary Disease

    approved small molecule active

    1 trial

  12. Dupilumab

    Regeneron UK Limited

    Atopic Dermatitis (AD)

    approved small molecule terminated

    2 trials

  13. Dupilumab

    Regeneron UK Limited

    Atopic Dermatitis

    approved small molecule active

    16 trials

  14. Dupilumab

    Regeneron UK Limited

    Asthma

    approved small molecule active

    13 trials

  15. Dupilumab

    Regeneron UK Limited

    Allergic Contact Dermatitis

    approved small molecule active

    1 trial

  16. Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]

    Regeneron UK Limited

    Eosinophilic Esophagitis (EoE)

    approved small molecule active

    1 trial

  17. Dupilumab Injectable Product

    Regeneron UK Limited

    Asthma

    approved small molecule active

    1 trial

  18. Dupilumab Only Product

    Regeneron UK Limited

    Atopic Dermatitis

    approved small molecule active

    1 trial

  19. Dupilumab Prefilled Syringe

    Regeneron UK Limited

    Nasal Polyps

    approved small molecule active

    1 trial

  20. Dupilumab SAR231893

    Regeneron UK Limited

    Dermatitis Atopic

    approved small molecule completed

    2 trials

  21. Dupilumab SAR231893

    Regeneron UK Limited

    Atopic Dermatitis

    approved small molecule completed

    1 trial

  22. Dupilumab SAR231893

    Regeneron UK Limited

    Chronic Rhinosinusitis With Nasal Polyps

    approved small molecule completed

    1 trial

  23. Dupilumab, dupilumab placebo, solution for injection in pre-filled syringe

    Sanofi-aventis Healthcare Pty Ltd

    Asthma

    approved small molecule active

    1 trial

  24. Dupixent

    Regeneron UK Limited

    Atopic Dermatitis

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources